by MM360 Staff | Jun 3, 2025 | Myeloma News
Source: Pharmacy Times articles Panelists discuss how ongoing monitoring and individualized treatment adjustments can help mitigate adverse events associated with low-density lipoprotein cholesterol (LDL-C)–lowering therapies while maintaining efficacy and explore...
by MM360 Staff | Jun 3, 2025 | Myeloma News
Source: Pharmacy Times articles Panelists discuss how key clinical and economic factors, such as efficacy, safety, cost-effectiveness, patient adherence, and proper monitoring, should be considered when evaluating new low-density lipoprotein cholesterol...
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles The CDC has updated its COVID-19 vaccine guidance for children and pregnant individuals, sparking a debate among health experts and concerns over insurance coverage. Read More
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Amid intensified scrutiny of COVID-19 vaccines at HHS, Moderna’s mRNA-1283 COVID-19 vaccine was granted FDA approval, for patients 65 years and older and patients aged 12 to 64 years with at least 1 or more underlying risk for severe...
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles A clinical trial shows tebipenem pivoxil hydrobromide (Tebipenem HBr; Spero Therapeutics and GSK) effectively treats complicated urinary tract infections (cUTIs), potentially transforming patient care and reducing hospital costs. Read...
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles The NJSHP’s 2nd Annual Symposium fosters networking and education for pharmacy professionals, featuring expert insights on compliance and regulation in pharmacy compounding. Read More